Literature DB >> 12238862

Recombinant factor VIIa after aortic valve replacement in a patient with osteogenesis imperfecta.

Marc Kastrup1, Christian von Heymann, Holger Hotz, Wolfgang F Konertz, Sabine Ziemer, Wolfgang J Kox, Claudia Spies.   

Abstract

A 26-year-old man with osteogenesis imperfecta and severe aortic regurgitation was scheduled for aortic valve replacement. As previously described by other authors the operation was difficult owing to the friability and weakness of the tissues. Mean blood losses of 153 mL per hour during the first 7 postoperative hours were observed. Despite normal coagulation indicators the bleeding did not stop and recombinant factor VIIa was applied at 40 microg/kg. Bleeding was successfully stopped after this single application.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12238862     DOI: 10.1016/s0003-4975(02)03700-1

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  1 in total

1.  Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant.

Authors:  Manish J Gandhi; Richard A Pierce; Lini Zhang; Marc R Moon; George J Despotis; Nader Moazami
Journal:  J Cardiothorac Surg       Date:  2007-07-06       Impact factor: 1.637

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.